Join the Oncology Brothers, in this insightful episode as they dive deep into the treatment algorithms for newly diagnosed multiple myeloma and smoldering myeloma. Featuring Gurbakhash Kaur, MD, a myeloma specialist from the Mount Sinai Hospital, the discussion covered the latest advancements in treatment options, including the recent approval of daratumumab for high-risk smoldering myeloma and the evolving landscape of frontline therapies.
In this episode, you'll learn about:
The definition of high-risk smoldering myeloma and the criteria for treatment versus active surveillance
The current treatment paradigms for newly diagnosed multiple myeloma, including the importance of quadruple therapy
Insights into managing frail patients and the considerations for transplant eligibility
The role of minimal residual disease (MRD) assessments in treatment decisions and maintenance therapy
The impact of cytopenias and how to manage them effectively
Whether you're a healthcare professional or someone interested in the latest in oncology, this episode provides valuable insights into the complexities of treating multiple myeloma. Don't miss out on this informative discussion!
Podden och tillhörande omslagsbild på den här sidan tillhör
Oncology Brothers. Innehållet i podden är skapat av Oncology Brothers och inte av,
eller tillsammans med, Poddtoppen.
